Fri, Aug 29, 2025
[Archive]
Volume 17, Issue 1 (March-2025 2025)
Iranian Journal of Blood and Cancer 2025, 17(1): 91-97 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jafari-Sales A, Nozohour-Leilabadi E, Safari M, Farahnaki-Sadabadi M, Yaghoubi-Azar N, Pashazadeh M. A Comprehensive Review of the Role of Viruses in the Onset and Progression of Lung Cancer. Iranian Journal of Blood and Cancer 2025; 17 (1) :91-97
URL: http://ijbc.ir/article-1-1701-en.html
URL: http://ijbc.ir/article-1-1701-en.html
Abolfazl Jafari-Sales1 
, Elham Nozohour-Leilabadi2 , Maryam Safari2 , Maryam Farahnaki-Sadabadi3 , Negin Yaghoubi-Azar2 , Mehrdad Pashazadeh *4
, Elham Nozohour-Leilabadi2 , Maryam Safari2 , Maryam Farahnaki-Sadabadi3 , Negin Yaghoubi-Azar2 , Mehrdad Pashazadeh *4
1- Department of Microbiology, Kaz.C., Islamic Azad University, Kazerun, Iran. & Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran.
2- Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran. & Department of Microbiology, Ta.C, Islamic Azad University, Tabriz, Iran.
3- Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran. & Department of Cellular and Molecular Biology, Ta.C., Islamic Azad University, Tabriz, Iran.
4- Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran. & Department of Laboratory Sciences and Microbiology, TaMS.C., Islamic Azad University, Tabriz, Iran. ,mehrdadpashazadeh85@gmail.com
2- Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran. & Department of Microbiology, Ta.C, Islamic Azad University, Tabriz, Iran.
3- Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran. & Department of Cellular and Molecular Biology, Ta.C., Islamic Azad University, Tabriz, Iran.
4- Infectious Diseases Research Center, TaMS.C., Islamic Azad University, Tabriz, Iran. & Department of Laboratory Sciences and Microbiology, TaMS.C., Islamic Azad University, Tabriz, Iran. ,
Abstract: (703 Views)
A number of variables may influence the development and spread of lung cancer (LC), one of the most prevalent and fatal cancers in the world. In this context, viruses are important, especially the human papillomavirus (HPV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), influenza virus (IV), and cytomegalovirus (CMV). These viruses can influence the development of LC through metabolic alterations, immune response suppression, and disruption of the tumor microenvironment (TME). Specifically, HPV may contribute to LC through genetic effects, while EBV can induce molecular changes in cells. HIV, by suppressing the immune system and increasing the risk of secondary infections, may create conditions conducive to the development of lung tumors. IV and CMV can also play a role in accelerating tumorigenic processes by impacting the immune system and promoting inflammation. This review article examines the various mechanisms by which viruses are involved in LC and their association with the progression of lung tumors. Additionally, the role of vaccination in preventing LC, particularly in individuals infected with specific viruses, is explored.
Keywords: Pulmonary neoplasms, Human papillomavirus, Epstein-Barr virus, Human immunodeficiency virus, Influenza virus, Cytomegalovirus
: Review Article |
Subject:
Immunology
Received: 2025/03/13 | Accepted: 2025/03/28 | Published: 2025/03/30
Received: 2025/03/13 | Accepted: 2025/03/28 | Published: 2025/03/30
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. [DOI:10.3322/caac.21492]
2. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemporary Oncology/Współczesna Onkologia. 2021;25(1):45-52. [DOI:10.5114/wo.2021.103829]
3. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nature reviews Clinical oncology. 2023;20(9):624-39. [DOI:10.1038/s41571-023-00798-3]
4. Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine. 2023;102(8):e32899. [DOI:10.1097/MD.0000000000032899]
5. Xiong W-M, Xu Q-P, Li X, Xiao R-D, Cai L, He F. The association between human papillomavirus infection and lung cancer: a system review and meta-analysis. Oncotarget. 2017;8(56):96419. [DOI:10.18632/oncotarget.21682]
6. Sequeira T, Pinto R, Cardoso C, Almeida C, Aragão R, Almodovar T, et al. HPV and Lung Cancer: A Systematic Review. Cancers. 2024;16(19):3325. [DOI:10.3390/cancers16193325]
7. Wang H. The interplay of EBV virus and cell metabolism in lung cancer. Journal of Cellular and Molecular Medicine. 2024;28(22):e70088. [DOI:10.1111/jcmm.70088]
8. Shannon-Lowe C, Adland E, Bell AI, Delecluse H-J, Rickinson AB, Rowe M. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. Journal of virology. 2009;83(15):7749-60. [DOI:10.1128/JVI.00108-09]
9. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, et al. HIV as an independent risk factor for incident lung cancer. Aids. 2012;26(8):1017-25. [DOI:10.1097/QAD.0b013e328352d1ad]
10. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Annals of internal medicine. 2015;163(7):507-18. [DOI:10.7326/M14-2768]
11. Angrini M, Varthaman A, Garcia-Verdugo I, Sallenave J-M, Alifano M, Cremer I. To vaccinate or not: influenza virus and lung cancer progression. Trends in Cancer. 2021;7(7):573-6. [DOI:10.1016/j.trecan.2021.02.006]
12. Harabajsa S, Šefčić H, Klasić M, Milavić M, Lepej SŽ, Grgić I, et al. Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma. Croatian medical journal. 2023;64(2):84. [DOI:10.3325/cmj.2023.64.84]
13. Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer: Epidemiology, diagnosis, and management. Indian Journal of Cancer. 2022;59(Suppl 1):S90-S105. [DOI:10.4103/ijc.IJC_52_21]
14. Ferone G, Lee MC, Sage J, Berns A. Cells of origin of lung cancers: lessons from mouse studies. Genes & development. 2020;34(15-16):1017-32. [DOI:10.1101/gad.338228.120]
15. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational lung cancer research. 2018;7(3):220. [DOI:10.21037/tlcr.2018.05.06]
16. Chen Y, Liu T, Xu Z, Dong M. Association of Epstein-Barr virus (EBV) with lung cancer: meta-analysis. Frontiers in Oncology. 2023;13:1177521. [DOI:10.3389/fonc.2023.1177521]
17. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Annals of global health. 2019;85(1):8. [DOI:10.5334/aogh.2419]
18. Osorio JC, Candia-Escobar F, Corvalán AH, Calaf GM, Aguayo F. High-risk human papillomavirus infection in lung cancer: mechanisms and perspectives. Biology. 2022;11(12):1691. [DOI:10.3390/biology11121691]
19. Frega S, Ferro A, Bonanno L, Guarneri V, Conte P, Pasello G. Lung cancer (LC) in HIV positive patients: pathogenic features and implications for treatment. International journal of molecular sciences. 2020;21(5):1601. [DOI:10.3390/ijms21051601]
20. Alexandrova Y, Costiniuk CT, Jenabian M-A. Pulmonary immune dysregulation and viral persistence during HIV infection. Frontiers in immunology. 2022;12:808722. [DOI:10.3389/fimmu.2021.808722]
21. Osorio JC, Blanco R, Corvalán AH, Muñoz JP, Calaf GM, Aguayo F. Epstein-Barr Virus infection in lung cancer: Insights and perspectives. Pathogens. 2022;11(2):132. [DOI:10.3390/pathogens11020132]
22. Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, et al. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proceedings of the National Academy of Sciences. 2020;117(2):1119-28. [DOI:10.1073/pnas.1904022116]
23. SÖDERBERG‐NAUCLÉR C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? Journal of internal medicine. 2006;259(3):219-46. [DOI:10.1111/j.1365-2796.2006.01618.x]
24. Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. American journal of roentgenology. 2011;196(2):287-95. [DOI:10.2214/AJR.10.5412]
25. Cao F, Li Y-Z, Zhang D-Y, Wang X-Y, Chen W-X, Liu F-H, et al. Human papillomavirus infection and the risk of cancer at specific sites other than anogenital tract and oropharyngeal region: an umbrella review. EBioMedicine. 2024;104. [DOI:10.1016/j.ebiom.2024.105155]
26. Gheit T. Mucosal and cutaneous human papillomavirus infections and cancer biology. Frontiers in oncology. 2019;9:355. [DOI:10.3389/fonc.2019.00355]
27. Nachira D, Congedo MT, D'Argento E, Meacci E, Evangelista J, Sassorossi C, et al. The Role of Human Papilloma Virus (HPV) in Primary Lung Cancer Development: State of the Art and Future Perspectives. Life. 2024;14(1):110. [DOI:10.3390/life14010110]
28. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus research. 2002;89(2):213-28. [DOI:10.1016/S0168-1702(02)00190-9]
29. Hussen BM, Ahmadi G, Marzban H, Azar MEF, Sorayyayi S, Karampour R, et al. The role of HPV gene expression and selected cellular MiRNAs in lung cancer development. Microbial pathogenesis. 2021;150:104692. [DOI:10.1016/j.micpath.2020.104692]
30. Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV. Current Opinion in HIV and AIDS. 2017;12(1):31-8. [DOI:10.1097/COH.0000000000000326]
31. Moltó J, Moran T, Sirera G, Clotet B. Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Translational lung cancer research. 2015;4(6):678.
32. Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology. 2015;12:1-17. [DOI:10.1186/s12977-015-0144-x]
33. Niedobitek G, Meru N, Delecluse HJ. Epstein‐Barr virus infection and human malignancies. International journal of experimental pathology. 2001;82(3):149-70.
https://doi.org/10.1111/j.1365-2613.2001.iep190.x [DOI:10.1046/j.1365-2613.2001.00190.x]
34. Becnel D, Abdelghani R, Nanbo A, Avilala J, Kahn J, Li L, et al. Pathogenic role of epstein-barr virus in lung cancers. Viruses. 2021;13(5):877. [DOI:10.3390/v13050877]
35. Odumade OA, Hogquist KA, Balfour Jr HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clinical microbiology reviews. 2011;24(1):193-209. [DOI:10.1128/CMR.00044-10]
36. Šimičić P, Batović M, Stojanović Marković A, Židovec-Lepej S. Deciphering the role of Epstein-Barr virus latent membrane protein 1 in immune modulation: A multifaced Signalling perspective. Viruses. 2024;16(4):564. [DOI:10.3390/v16040564]
37. Nkosi D, Sun L, Duke LC, Meckes Jr DG. Epstein-Barr virus LMP1 manipulates the content and functions of extracellular vesicles to enhance metastatic potential of recipient cells. PLoS pathogens. 2020;16(12):e1009023. [DOI:10.1371/journal.ppat.1009023]
38. Hsu C-L, Chang Y-S, Li H-P. Molecular diagnosis of nasopharyngeal carcinoma: Past and future. Biomedical Journal. 2024:100748. [DOI:10.1016/j.bj.2024.100748]
39. Hu J, Li Y, Li H, Shi F, Xie L, Zhao L, et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Theranostics. 2020;10(26):11921. [DOI:10.7150/thno.46006]
40. Pietropaolo V, Prezioso C, Moens U. Role of virus-induced host cell epigenetic changes in cancer. International Journal of Molecular Sciences. 2021;22(15):8346. [DOI:10.3390/ijms22158346]
41. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol Mech Dis. 2008;3(1):499-522. [DOI:10.1146/annurev.pathmechdis.3.121806.154316]
42. Weng C-F, Chen L-J, Lin C-W, Chen H-M, Lee HH-C, Ling T-Y, et al. Association between the risk of lung cancer and influenza: A population-based nested case-control study. International journal of infectious diseases. 2019;88:8-13. [DOI:10.1016/j.ijid.2019.07.030]
43. Brown E. Influenza virus genetics. Biomedicine & Pharmacotherapy. 2000;54(4):196-209. [DOI:10.1016/S0753-3322(00)89026-5]
44. Chen K-Y, Wu S-M, Liu J-C, Lee K-Y. Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population-based cohort study. Medicine. 2019;98(47):e18035. [DOI:10.1097/MD.0000000000018035]
45. Koutsakos M, McWilliam HE, Aktepe TE, Fritzlar S, Illing PT, Mifsud NA, et al. Downregulation of MHC class I expression by influenza A and B viruses. Frontiers in immunology. 2019;10:1158. [DOI:10.3389/fimmu.2019.01158]
46. A Ross S, Novak Z, Pati S, B Boppana S. Overview of the diagnosis of cytomegalovirus infection. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders). 2011;11(5):466-74. [DOI:10.2174/187152611797636703]
47. Freeman Jr R. The 'indirect'effects of cytomegalovirus infection. American Journal of Transplantation. 2009;9(11):2453-8. [DOI:10.1111/j.1600-6143.2009.02824.x]
48. El Baba R, Herbein G. Immune landscape of CMV infection in cancer patients: from "canonical" diseases toward virus-elicited oncomodulation. Frontiers in immunology. 2021;12:730765. [DOI:10.3389/fimmu.2021.730765]
49. Li M-Y, Liu L-Z, Dong M. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. Molecular cancer. 2021;20(1):22. [DOI:10.1186/s12943-021-01312-y]
50. Frydrychowicz M, Kolecka‐Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes-structure, biogenesis and biological role in non‐small‐cell lung cancer. Scandinavian journal of immunology. 2015;81(1):2-10. [DOI:10.1111/sji.12247]
51. Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, et al. Dendritic cell derived-exosomes: biology and clinical implementations. Journal of leukocyte biology. 2006;80(3):471-8. [DOI:10.1189/jlb.0206094]
52. Hannafon BN, Ding W-Q. Intercellular communication by exosome-derived microRNAs in cancer. International journal of molecular sciences. 2013;14(7):14240-69. [DOI:10.3390/ijms140714240]
53. Xu K, Zhang C, Du T, Gabriel ANA, Wang X, Li X, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomedicine & Pharmacotherapy. 2021;134:111111. [DOI:10.1016/j.biopha.2020.111111]
54. Hamann HA, Ver Hoeve ES, Carter-Harris L, Studts JL, Ostroff JS. Multilevel opportunities to address lung cancer stigma across the cancer control continuum. Journal of Thoracic Oncology. 2018;13(8):1062-75. [DOI:10.1016/j.jtho.2018.05.014]
55. Dioverti MV, Razonable RR. Cytomegalovirus. Diagnostic Microbiology of the Immunocompromised Host. 2016:97-125. [DOI:10.1128/9781555819040.ch4]
56. Massion PP, Carbone DP. The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respiratory research. 2003;4:1-15. [DOI:10.1186/1465-9921-4-12]
57. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular cancer. 2023;22(1):40. [DOI:10.1186/s12943-023-01740-y]
58. Bunn Jr PA. Worldwide overview of the current status of lung cancer diagnosis and treatment. Archives of pathology & laboratory medicine. 2012;136(12):1478-81. [DOI:10.5858/arpa.2012-0295-SA]
59. Ahmad J, Akhter S, Rizwanullah M, Amin S, Rahman M, Ahmad MZ, et al. Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnology, science and applications. 2015:55-66. [DOI:10.2147/NSA.S49052]
60. Garbuzenko OB, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer biology & medicine. 2014;11(1):44-55.
61. Lee W-H, Loo C-Y, Traini D, Young PM. Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. Asian journal of pharmaceutical sciences. 2015;10(6):481-9. [DOI:10.1016/j.ajps.2015.08.009]
62. Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharmaceutica Sinica B. 2018;8(3):440-8. [DOI:10.1016/j.apsb.2018.03.004]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
